Lung damage in SARS-CoV-2 patients: An autopsy study in the era of vaccination.
COVID‐19
SARS‐CoV‐2
mortality
post‐mortem analysis
vaccination
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
29 Sep 2024
29 Sep 2024
Historique:
received:
22
07
2024
accepted:
19
09
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
The contribution of SARS-CoV-2 infection on lung damage and the effect of vaccination on either containing the number of deaths or mitigating lung damage has not been systematically investigated. Post-mortem analysis was performed among consecutive in-patients with COVID-19 deceased in the Province of Trieste (2020-2022). The outcomes of the study were (i) rates of in-hospital mortality, (ii) contribution of COVID-19 to death, (iii) histological extent of lung injury and (iv) impact of vaccination. A total of 1038 consecutive hospitalized patients who died with SARS-CoV-2 infection were autopsied and deep histological analysis of the lungs was performed in a randomly selected sample of 508 cases. Among them, SARS-CoV-2 infection was (a) the cause of death (n = 90), (b) contributing to death (n = 304) and (c) an accompanying feature (n = 114). The incidence of SARS-CoV-2 infection as the primary cause of mortality decreased over time (23.8% in 2020, 20.9% in 2021 and 7.9% in 2022). On multivariable analysis, vaccination (any dose) was independently associated with lower rates of death related to SARS-CoV-2 infection (HR .15, p < .001), after adjusting for other independent predictors. A total of 172 patients were vaccinated at least with two doses at the time of death: 93% triple-vaccinated, 7% double-vaccinated. On histological analysis, vaccinated patients had a greater frequency of pneumonia severity score 0 and 1 (20.3% vs. 5.4% and 20.9% vs. 7.7%, p < .001, respectively), and a substantially lower proportion of pneumonia severity score 3 (26.2% vs. 55.1%, p < .001) compared to unvaccinated patients. COVID-19 vaccination has substantially reduced rates of death related to SARS-CoV-2 infection over time and may have the ability to mitigate lung damage.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14325Informations de copyright
© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID‐19. Nat Med. 2023;29(2):334‐343.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239‐1242.
Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid‐19. N Engl J Med. 2020;383(2):120‐128.
Liu J, Li Y, Liu Q, et al. SARS‐CoV‐2 cell tropism and multiorgan infection. Cell Discov. 2021;7:17.
Liu F, Han K, Blair R, et al. SARS‐CoV‐2 infects endothelial cells in vivo and in vitro. Front Cell Infect Microbiol. 2021;11:701278.
Bozio CH, Butterfield KA, Briggs Hagen M, et al. Protection from COVID‐19 mRNA vaccination and prior SARS‐CoV‐2 infection against COVID‐19‐associated encounters in adults during delta and omicron predominance. J Infect Dis. 2023;227(12):1348‐1363.
Barda N, Dagan N, Ben‐Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid‐19 vaccine in a Nationwide setting. N Engl J Med. 2021;385(12):1078‐1090.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383(27):2603‐2615.
Sinagra G, Merlo M, Porcari A. Exploring the possible link between myocarditis and mRNA COVID‐19 vaccines. Eur J Intern Med. 2021;92:28‐30.
Ssentongo P, Ssentongo AE, Voleti N, et al. SARS‐CoV‐2 vaccine effectiveness against infection, symptomatic and severe COVID‐19: a systematic review and meta‐analysis. BMC Infect Dis. 2022;22(1):439.
Bussani R, Schneider E, Zentilin L, et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID‐19 pathology. EBioMedicine. 2020;61:103104.
Dal Ferro M, Bussani R, Paldino A, et al. SARS‐CoV‐2, myocardial injury and inflammation: insights from a large clinical and autopsy study. Clin Res Cardiol. 2021;110(11):1822‐1831.
Bussani R, Zentilin L, Correa R, et al. Persistent SARS‐CoV‐2 infection in patients seemingly recovered from COVID‐19. J Pathol. 2023;259(3):254‐263.
Nab L, Parker EPK, Andrews CD, et al. Changes in COVID‐19‐related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health. 2023;8(5):e364‐e377.
Meslé MMI, Brown J, Mook P, et al. Estimated number of lives directly saved by COVID‐19 vaccination programs in the WHO European region, December 2020 to march 2023. medRxiv. 2024;12(9):714‐727.
HDR UK COALESCE Consortium. Undervaccination and severe COVID‐19 outcomes: meta‐analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales. Lancet (London, England). 2024;403:554‐566.
Colombo D, Del Nonno F, Marchioni L, et al. Autopsies revealed pathological features of COVID‐19 in unvaccinated vs vaccinated patients. Biomedicine. 2023;11(2):551.
Schwab C, Merle U, Schirmacher P, Longerich T. Lethality of SARS‐CoV‐2 infection‐a comparative autopsy study focusing on COVID‐19 development and virus variants. Histopathology. 2023;83(2):242‐251.
Le Rutte EA, Shattock AJ, Marcelino I, Goldenberg S, Penny MA. Efficacy thresholds and target populations for antiviral COVID‐19 treatments to save lives and costs: a modelling study. eClinicalMedicine. 2024;73:102683.